Author:
Shu Yujing,Otake Masato,Seta Yasuhiro,Hori Keigo,Kuramochi Akiko,Ohba Yoshio,Teramura Yuji
Abstract
AbstractAlthough stem cell-based regenerative medicine has been extensively studied, it remains difficult to reconstruct three dimensional tissues and organs in combination with vascular systems in vitro. One clinically successful therapy is transplantation of mesenchymal stem cells (MSC) into patients with graft versus host disease. However, transplanted cells are immediately damaged and destroyed because of innate immune reactions provoked by thrombogenic inflammation, and patients need to take immunosuppressive drugs for the immunological regulation of allogeneic cells. This reduces the benefits of stem cell transplantation. Therefore, alternative therapies are more realistic options for clinical use. In this study, we aimed to take advantage of the therapeutic efficacy of MSC and use multiple cytokines released from MSC, that is, stem cells from human exfoliated deciduous teeth (SHEDs). Here, we purified components from conditioned media of immortalized SHED (IM-SHED-CM) and evaluated the activities of intracellular dehydrogenase, cell migration, and antioxidative stress by studying the cells. The immortalization of SHED could make the stable supply of CM possible. We found that the fractionated component of 50–100 kD from IM-SHED-CM had higher efficacy than the original IM-SHED-CM in terms of intracellular dehydrogenase and cell migration in which intracellular signal transduction was activated via receptor tyrosine kinases, and the glutathione peroxidase and reductase system was highly active. Although antioxidative stress activities in the fractionated component of 50–100 kD had slightly lower than that of original IM-SHE-CM, the fraction still had the activity. Thus, the use of fractionated components of 50–100 kD from IM-SHED-CM could be an alternative choice for MSC transplantation because the purified components from CM could maintain the effect of cytokines from SHED.
Publisher
Springer Science and Business Media LLC
Reference44 articles.
1. Passier, R., van Laake, L. W. & Mummery, C. L. Stem-cell-based therapy and lessons from the heart. Nature 453(7193), 322–329 (2008).
2. Miura, K. et al. Variation in the safety of induced pluripotent stem cell lines. Nat. Biotechnol. 27(8), 743–745 (2009).
3. Hamidieh, A. A., Verdi, J. & Shoae-Hassani, A. Safe transplantation of pluripotent stem cell by preventing teratoma. J. Clin. Investig. 122, 80–90 (2014).
4. Hurd, M. D., Goel, I., Sakai, Y. & Teramura, Y. Current status of ischemic stroke treatment: From thrombolysis to potential regenerative medicine. Regen. Ther. 18, 408–417 (2021).
5. Honmou, O. et al. Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain 134(6), 1790–1807 (2011).